by kwal1 | Jul 16, 2019 | News
SGM-101 has the potential to be the first tumor-targeted fluorescent probe to be marketed for fluorescence-guided surgery (FGS). Montpellier, France, 16 July 2019 – SurgiMab today announces that the first surgical procedure was carried out in a pivotal Phase 3...
by kwal1 | Jan 31, 2018 | News
Dr. Alex Vahrmeijer’s team in Leiden publishes first results of the clinical use of SGM-101. Montpellier, France 31st Jan 2018 – SurgiMab is very proud to announce that Dr. Alex Vahrmeijer’s team in Leiden University Medical Center (LUMC) published their...
by kwal1 | Jan 11, 2018 | News
SurgiMab sponsors the Molecular Guided Surgery conference that will take place during the SPIE Photonics West in San Francisco, 27-28 Jan 2018. Montpellier, France Jan 2018 – SurgiMab is proud to be a sponsor of the Molecular Guided Surgery conference that will take...
by kwal1 | Sep 19, 2017 | News
SurgiMab and Quest Medical Imaging enter a Collaboration Agreement for the 1st Phase III multicenter clinical trial on Fluorescence Guided Surgery for Digestive Cancers. Montpellier, France and Middenmeer, Holland – 18 sept 2017 – SurgiMab and Quest Medical...
by kwal1 | May 11, 2017 | News
SurgiMab is an Entrepreneur Sponsor of the first Boston-Paris Biotechnology Summit and as such, we will present our latest clinical developments during the Entrepreneurs Forum. The Boston-Paris Biotechnology Summit is a novel catalyst event aiming to provide...
by kwal1 | Mar 29, 2017 | News
SurgiMab is happy to announce the publication of its manuscript entitled “SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery” in the peer-reviewed journal Surgical Oncology. This paper describes the...
